Glass globe and stethoscope laying on a keyboard

Corporate Affairs in the Pharmaceutical Industry: How to Succeed in a Complex and Evolving Landscape

September 30, 2024

By the year 2030, global pharmaceutical demand is expected to grow more than 6% with expenditures approaching USD$1.5 trillion. Layered above this growth are complexities including new modalities, the increased reliance on artificial intelligence (AI) for drug discovery and development, improved manufacturing efficiency, more efficient and reliable supply chains and changing policies on product pricing, access and corporate governance, coupled with the requirements associated with reporting on environmental, social and governance (ESG) and diversity, equity and inclusion (DEI).

Corporate affairs leaders at the helm of pharmaceutical brands face a challenging task: connect a myriad of factors that are constantly changing and impacting the business differently over time, while also maintaining the confidence of investors, partners and other stakeholders. Through corporate affairs, the business seeks to build and protect reputation, cultivate trust, build an efficient, accurate and robust information conduit that may be relied upon by employees and business leaders alike and perform the daily work of corporate communications.

Download the full white paper here.

Related Articles

Volume digital

Perspectives

The Volume Trap: Using AI to Move from Noise to Meaning

September 10, 2025
Executive woman leading a business meeting

Perspectives

$11.9 Trillion Reasons to Rethink the CCO’s Role

September 11, 2025
AI and keyboard

Perspectives

The Great AI Race: China’s Approach to Developing Its AI Industry

September 4, 2025